Coping strategies used by patients infected with hepatitis C virus who are facing medication costs

Canadian Journal of Hospital Pharmacy

Volumn 64, Issue 2, 2011, Pages 131-140

  Sanyal, Chiranjeev ^a   Ingram, Ethel Langille ^a   Sketris, Ingrid S ^a   Peltekian, Kevork M ^a   Kirkland, Susan ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chronic disease; Coping strategies; Cost of medications; Hepatitis C virus; Pharmacists; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; DERMATOLOGICAL AGENT; DIURETIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; COPING BEHAVIOR; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH STATUS; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCOME; INTERVIEW; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRESCRIPTION;

EID: 84055218966     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: 10.4212/cjhp.v64i2.997     Document Type: Article

References (57)

1. Responding to the epidemic: recommendations for a Canadian hepatitis C strategy. Hepatitis C Collaboration; 2005 Sep [cited 2010 Aug 27]. Available from: www.cdnaids.ca/web/repguide.nsf/CL/084A3FABFBD4DA96852570C800730B23/ $file/Responding-e.pdf
2. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90(10):1562-1569.
3. Remis RS. Modelling the incidence and prevalence of hepatitis C and its sequelae in Canada, 2007. Final report. Ottawa (ON): Public Health Agency of Canada, Infectious Disease and Emergency Preparedness Branch, Centre for Communicable Diseases and Infection Control, Community Acquired Infections Division; 2007.
4. Peltekian K. A collaborative model for viral hepatitis service [abstract]. In: New Knowledge, New Hope: Proceedings of the 2nd Canadian Conference on Hepatitis C; 2004 Mar 27-30; Vancouver (BC).
5. Nova Scotia Department of Health, Office of the Chief Medical Officer of Health. Hepatitis C surveillance report 2004. Halifax (NS): Nova Scotia Department of Health; 2005 Jun.
6. Wilkins T, Malcolm J, Raina D, Schade R. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010;81(11):1351-1357.
7. Brady B, Siebert U, Sroczynski G, Murphy G, Husereau D, Sherman M, et al. Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation. Technol Rep 82. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2007.
8. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7(1):261-287. (Pubitemid 36350763)
9. White CP, Hirsch G, Patel S, Adams F, Peltekian K. Complementary and alternative medicine use by patients chronically infected with hepatitis C virus. Can J Gastroenterol 2007;21(9):589-595. (Pubitemid 350011443)
10. Grootendorst P. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. Can J Clin Pharmacol 2002;9(2):79-99. (Pubitemid 35012823)
11. Romanow RJ, chair. Building on values: the future of health care in Canada. Final report. Saskatoon (SK): Commission on the Future of Health Care in Canada; 2002.
12. Kirby M, chair. The health of Canadians - the federal role. Ottawa (ON): Standing Senate Committee on Social Affairs, Science and Technology; 2002.
13. Phillips K. Catastrophic drug coverage in Canada. Report PRB 09-06E. Ottawa (ON): Library of Parliament, Parliamentary Information and Research Service; 2009 Sep 1.
14. Briesacher B, Ross-Degnan D, Adams A, Wagner A, Gurwitz J, Soumerai SB. A new measure of medication affordability. Soc Work Public Health 2009;24(6):600-612.
15. Schafheutle E, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002;10(3):187-195. (Pubitemid 36844273)
16. Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Policy 2005;4(1):23-35. (Pubitemid 41352123)
17. Cronk A, Humphries TL, Delate T, Clark D, Morris B. Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. Am J Health Syst Pharm 2008;65(11):1062-1070. (Pubitemid 351768742)
18. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 2004;292(8):952-960. (Pubitemid 39097205)
19. Kennedy J, Morgan S. A cross-national study of prescription nonadherence due to cost: data from the Joint Canada-United States Survey of Health. Clin Ther 2006;28(8):1217-1224. (Pubitemid 44376807)
20. Schafheutle E. The impact of prescription charges on asthma patients is uneven and unpredictable: evidence from qualitative interviews. Prim Care Respir J 2009;18(4):266-272.
21. Brixner DI. The case against excessive cost sharing. Am J Manag Care 2006;12(6 Suppl):S162,S164; discussion S167-S172; quiz S173-S176.
22. Prescription drug coverage. Halifax (NS): Province of Nova Scotia, Community Services; 2011 [cited 2011 Apr 14]. Available from: www.gov.ns.ca/coms/employment/income-assistance/Pharmacare.html
23. Treatment coverage in your region [website]. Canadian AIDS Treatment Information Exchange; [cited 2010 Aug 9]. Available from: www. infohepatitec.ca/en/detail/treatment/region/NS
24. Schafheutle E, Hassell H, Noyce PR. Coping with prescription charges in the UK. Int J Pharm Pract 2004;12:239-246. (Pubitemid 39576438)
25. Low income cut-offs for 2007 and low income measures 2006. Income Res Pap Ser. Cat. no. 75F0002M No.004. Ottawa (ON): Statistics Canada; 2009 Jun.
26. Flood CM, Thomas B. Blurring of the public/private divide: the Canadian chapter. Eur J Health Law 2010;17(2):257-278.
27. Canada Health Act, RSC 1985, c. C-6. Available from: http://laws. justice.gc.ca/en/C-6/index.htmlAct [current to 2010 Jun 16; cited 2010 Aug 27].
28. Kapur V, Basu K. Drug coverage in Canada: who is at risk? Health Policy 2005;71(2):181-193. (Pubitemid 39647629)
29. Nova Scotia Family Pharmacare. Halifax (NS): Government of Nova Scotia; 2011 [cited 2011 Apr 14]. Available from: www.gov.ns.ca/health/ Pharmacare/family-pharmacare/family-pharmacare.asp
30. Coombes ME, Morgan SG, Barer ML, Pagliccia N. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs? Healthc Q 2004;7(4 Suppl): 13-19.
31. Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J. Effect of copayments on drug use in the presence of annual payment limits. Am J Manag Care 2007;13(6 Pt 2):328-334. (Pubitemid 46983129)
32. Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X, et al. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ 2005;173(11):1335-1340.
33. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285(4):421-429. (Pubitemid 32097260)
34. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med 1987;317(9):550-556. (Pubitemid 17123270)
35. Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int J Equity Health 2008;7(12):1-22.
36. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006;354(22):2349-2359. (Pubitemid 43801280)
37. Reed M, Brand R, Newhouse JP, Selby JV, Hsu J. Coping with prescription drug cost sharing: knowledge, adherence, and financial burden. Health Serv Res 2008;43(2):785-797. (Pubitemid 351442595)
38. Pham HH, Alexander GC, O'Malley AS. Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med 2007;167(7):663-668. (Pubitemid 46598458)
39. Alexander GC, Casalino LP, Meltzer DO. Physician strategies to reduce patients' out-of-pocket prescription costs. Arch Intern Med 2005;165(6):633-636. (Pubitemid 40393144)
40. Alexander GC, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med 2004;19(8):856-860. (Pubitemid 39096358)
41. Khan S, Sylvester R, Scott D, Pitts B. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states. J Manag Care Pharm 2008;14(8):780-789.
42. Desai S, Chen G, Hirsch G, Quinn A, Peltekian K. Referral patterns of Hepatology Services outpatient clinic: wait time from referral to visit by rule of sevens [abstract]. Can J Gastroenterol 2004;18 Suppl A:S140.
43. Kontorinis N, Garas G, Young J, Speers D, Chester BP, MacQuillan GC, et al. Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic. Intern Med J 2003;33(11):500-504. (Pubitemid 37494506)
44. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993;307(6908):846-848 (Pubitemid 23281752)
45. Jones I, Britten N. Why do some patients not cash their prescriptions? Br J Gen Pract 1998;48(426):903-905. (Pubitemid 28033631)
46. Schafheutle EI, Hassell K, Seston EM, Noyce PR. Non-dispensing of NHS prescriptions in community pharmacies. J Pharm Pract 2002;10(1):11-15. (Pubitemid 34298437)
47. Groves KE, Sketris I, Tett SE. Prescription drug samples - does this marketing strategy counteract policies for quality use of medicines? J Clin Pharm Ther 2003;28(4):259-271. (Pubitemid 37041133)
48. Piette J, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004;27(2):384-391. (Pubitemid 38174062)
49. Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, et al. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol 2010;44(2):e40-e45.
50. Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003;290(7):953-958. (Pubitemid 37430470)
51. Barry CA, Bradley CP, Britten N, Stevenson FA, Barber N. Patients'unvoiced agendas in general practice consultations: qualitative study. BMJ 2000;320(7244):1246-1250. (Pubitemid 30240475)
52. Piette JD, Heisler M, Horne R, Caleb Alexander G. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures. Soc Sci Med 2006;62(4):846-857. (Pubitemid 43087360)
53. Nichols-English GJ, Poirier S. Adherence to pharmaceutical care. In: DiPiro JT, editor. Encyclopedia of clinical pharmacy. New York (NY): Marcel Dekker, Inc; 2003. p. 10-22.
54. Cameron B. The impact of pharmacy discharge planning on continuity of care. Can J Hosp Pharm 1994;47(3):101-109. (Pubitemid 24249749)
55. Layson-Wolf C, Morgan JA. Pharmacy continuity of care: what do community pharmacists need from an acute care hospital to improve continuity of pharmaceutical care? Dis Manag Health Outcomes 2008;16(4):199-203.
56. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond C, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. Cochrane Database Syst Rev 2010;(7):CD000336.
57. Lehnbom EC, Brien JA. Challenges in chronic illness management: a qualitative study of Australian pharmacists' perspectives. Pharm World Sci 2010;32(5):631-636.